TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 08, 2022 06:45 ET | TCR2 Therapeutics
- gavo-cel Phase 1 trial dataset anticipated in September 2022- Initial TC-510 Phase 1 data anticipated in 2H 2022 - Expansion of manufacturing capacity and commencement of gavo-cel clinical trial...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022 17:15 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:15 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer
June 27, 2022 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 16:21 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics to Participate in Two Upcoming Conferences in June
June 01, 2022 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 12, 2022 06:45 ET | TCR2 Therapeutics
- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial- IND Clearance for Phase 1/2 clinical trial of TC-510- 30 patients treated with gavo-cel in the expanded Phase 1 trial;...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022 17:32 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022 16:15 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering...
TCR2-Brand-Logo-CMYK-FullColor-042921.png
TCR² Therapeutics Reports Fourth Quarter 2021 Financial Results and Provides Corporate Update
March 22, 2022 06:45 ET | TCR2 Therapeutics
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients...